Piper Sandler Cuts Zoetis (NYSE:ZTS) Price Target to $80.00

Zoetis (NYSE:ZTS) had its target price lowered by Piper Sandler from $90.00 to $80.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

ZTS has been the subject of several other reports. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup cut their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Stifel Nicolaus reduced their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, William Blair reiterated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Trading Down 2.5%

Shares of Zoetis stock opened at $73.47 on Monday. The firm’s 50 day moving average is $76.49 and its 200 day moving average is $99.53. The firm has a market capitalization of $30.36 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 1.30 and a beta of 0.74. Zoetis has a 1 year low of $71.45 and a 1 year high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm earned $1.76 EPS. The firm’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts forecast that Zoetis will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 34.93%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZTS. Westport Asset Management Inc. acquired a new position in Zoetis during the 2nd quarter worth about $287,000. Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter valued at about $302,601,000. Wealthfront Advisers LLC increased its stake in shares of Zoetis by 80.2% in the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after buying an additional 33,873 shares during the period. Main Street Financial Solutions LLC acquired a new stake in shares of Zoetis in the second quarter valued at about $3,819,000. Finally, First National Bank of Omaha raised its position in shares of Zoetis by 16.5% during the second quarter. First National Bank of Omaha now owns 3,882 shares of the company’s stock worth $284,000 after acquiring an additional 551 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup maintained a “buy” rating despite lowering its price target from $112 to $96, while BNP Paribas Exane maintained an “outperform” rating and reduced its target from $146 to $110. Both targets imply substantial upside from current levels. Citigroup and BNP Paribas Exane price target updates
• Positive Sentiment: Recent analyst coverage remains mixed rather than uniformly bearish: HSBC issued a “buy” rating, and the median price target from seven analysts is $99. Zoetis also reported quarterly earnings slightly above consensus and has recently attracted purchases from some institutional investors and company insiders.
• Neutral Sentiment: The broader analyst consensus is “hold,” reflecting uncertainty over the pace of recovery. Zacks Research separately downgraded the stock from “hold” to “strong sell,” highlighting the increasingly divided view on Zoetis’ near-term prospects. Zacks Research rating update
• Negative Sentiment: Investors remain concerned about softer U.S. companion-animal demand, including fewer veterinary visits, greater price sensitivity among pet owners and heavier competition in dermatology and parasiticides. These pressures have affected key brands and contributed to weaker sales trends. Zoetis pet-care demand and competitive pressure analysis
• Negative Sentiment: Zoetis reduced its 2026 revenue-growth and adjusted-earnings outlook in May. The market is still digesting the lower expectations, while recent target cuts from Piper Sandler, Citigroup and BNP Paribas Exane have reinforced concerns that a recovery may take longer than expected. Piper Sandler forecast for Zoetis
• Negative Sentiment: The stock recently reached a new 52-week low after an analyst downgrade, intensifying technical and sentiment pressure. Although quarterly EPS exceeded estimates, revenue fell slightly year over year and missed consensus, limiting the positive impact of the earnings beat. Zoetis 52-week low report

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.